Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paola Queirolo, Michele Maio(University of Siena), Alessandro Testori(European Organisation for Research and Treatment of Cancer), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Lorenza Di Guardo(Fondazione IRCCS Istituto Nazionale dei Tumori), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Ruggero Ridolfi, Jacopo Pigozzo(Istituto Oncologico Veneto), Francesco Cognetti(Apple (Israel)), Massimo Aglietta(Verizon (United States)), Michele Guida(Istituto Tumori Bari), Maresa Altomonte(University of Siena), Riccardo Marconcini(Azienda Ospedaliera Universitaria Pisana), Ester Simeone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carolina Cimminiello(Fondazione IRCCS Istituto Nazionale dei Tumori), Maria Grazia Bernengo(University of Turin), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Gaetana Rinaldi(AOL (United States)), Mario Mandalà(University of Perugia)
Cited by 164
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k